Evicenter
Keytruda (pembrolizumab) in High-risk early-stage triple-negative breast cancer
Manufacturer
Merck Sharp & Dohme LLC
Prescribing information
Keytruda (opens in a new tab)
Questions
28
Last updated

All questions

Indication: Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer

4 questions · 2 sources

Indication

What is KEYTRUDA (pembrolizumab) approved for in early-stage triple-negative breast cancer?

Can KEYTRUDA QLEX (subcutaneous pembrolizumab) be used instead of IV KEYTRUDA for early-stage TNBC?

Drug names

What is the generic name of KEYTRUDA?

Testing

Does PD-L1 expression affect KEYTRUDA eligibility in early-stage TNBC?

Note: The first passage heads a hypothetical patient profile based on patients studied in KEYNOTE-522; the second is a KEYNOTE-522 inclusion criterion.